The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "psoriasis"

Search results for: psoriasis

Long-Term Therapy with Lilly Drug Found to Help Plaque Psoriasis

June 8, 2016 • By Gene Emery

NEW YORK (Reuters Health)—Aggregated results from three studies of patients with moderate to severe plaque psoriasis show that Eli Lilly’s injectable drug ixekizumab can completely resolve the plaques in about one third of cases after 12 weeks of treatment. And with continued therapy every four weeks, at least half maintained or attained complete resolution of… [Read More]

Filed Under: Drug Updates Tagged With: clinical trials, ixekizumab, plaque psoriasis

Etanercept Submitted to FDA for Approval to Treat Pediatric Plaque Psoriasis; Boehringer Ingelheim & AbbVie to Collaborate; Low Doses of Gerilimzumab Promising for RA

April 13, 2016 • By Michele B. Kaufman, PharmD, BCGP

The FDA has received an application to expand the use of etanercept to treat plaque psoriasis in pediatric patients. Boehringer Ingelheim and AbbVie have announced a collaborative partnership to develop treatments for multiple autoimmune diseases. And gerilimzumab may prove safe and effective for treating inflammatory diseases at very low doses…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: etanercept, gerilimzumab, Inflammatory Disease, monoclonal antibody, plaque psoriasis, Rheumatoid Arthritis (RA)

U.S. FDA Approves Lilly’s Ixekizumab for Plaque Psoriasis

March 25, 2016 • By Reuters Staff

(Reuters)—U.S. health regulators said on Tuesday they have approved a drug from Eli Lilly and Co. to treat adults with moderate to severe cases of plaque psoriasis. The injectable drug known chemically as ixekizumab will be sold under the brand name Taltz, the U.S. Food and Drug Administration said. Taltz works by blocking interleukein-17A, a… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: FDA, Food and Drug Administration, ixekizumab, plaque psoriasis, skin

Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity

March 23, 2016 • By Michele B. Kaufman, PharmD, BCGP

In a 52-week clinical trial, patients with plaque psoriasis who took secukinumab achieved greater sustained skin clearance then those taking ustekinumab. Also, three clinical trials showed ixekizumab improves work productivity in patients with plaque psoriasis…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: ixekizumab, plaque psoriasis, productivity, secukinumab, skin, ustekinumab, workplace

Psoriasis Drug Succeeds in Mid-Stage Study

March 17, 2016 • By Reuters Staff

(Reuters)—Drug developer Vitae Pharmaceuticals Inc. said its experimental psoriasis drug significantly reduced the skin condition in patients from a mid-stage trial, sending its shares up 70% in after-hours trading. Patients taking a 350 mg dose of the drug, VTP-43742, showed a 24% reduction, while patients who took the 700 mg dose showed a 30% reduction… [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Psoriasis, secukinumab, skin, VTP-43742

Tofacitinib Shows Ongoing Action Against Plaque Psoriasis

March 3, 2016 • By David Douglas

NEW YORK (Reuters Health)—The oral Janus kinase inhibitor tofacitinib (Xeljanz, Pfizer) shows long-term efficacy against chronic plaque psoriasis, according to findings from two randomized studies and an extension trial. The outcome, Dr. Svitlana Tatulych told Reuters Health by email, “demonstrated that oral tofacitinib, at both the 10 mg and 5 mg twice-daily doses, provided sustained… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: Janus Kinase Inhibitors, plaque psoriasis, Tofacitinib

Etanercept Biosimilar Approved in EU, Plus FDA Reviews Brodalumab for Plaque Psoriasis

February 3, 2016 • By Michele B. Kaufman, PharmD, BCGP

An etanercept biosimilar referencing Enbrel and designed to treat multiple autoimmune diseases has been approved for the European market. Also, an application for subcutaneous brodalumab to treat plaque psoriasis has been submitted to the FDA…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biosimilars, brodalumab, etanercept, European Union, FDA, Food and Drug Administration

One-Year Data Shows Apremilast Effective in Severe Scalp, Nail Psoriasis

November 30, 2015 • By Reuters Staff

NEW YORK (Reuters Health)—Apremilast is effective in patients with difficult to treat psoriasis of the scalp and nails, according to long-term results of two phase 3 trials. Investigators had previously reported 16-week data from the Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis (ESTEEM) 1 and 2 trials. The new report includes… [Read More]

Filed Under: DMARDs & Immunosuppressives, Drug Updates Tagged With: apremilast, nails, Psoriasis, Psoriatic Arthritis, scalp

Bariatric Surgery Tied to Improvement in Psoriasis, Psoriatic Arthritis

November 11, 2015 • By Megan Brooks

NEW YORK (Reuters Health)—Obese patients with psoriasis or psoriatic arthritis are apt to experience significant symptomatic relief following bariatric surgery, according to a new chart review. Specifically, the study found that more than half of the patients with psoriasis or psoriatic arthritis reported improvements in their disease following surgery. Dr. Soumya Reddy, assistant professor of… [Read More]

Filed Under: Conditions, Systemic Inflammatory Syndromes Tagged With: bariatric surgery, Obesity, Psoriasis, Psoriatic Arthritis

German Registry Evaluates Systemic Psoriasis Treatments

November 4, 2015 • By Michele B. Kaufman, PharmD, BCGP

The German Psoriasis Registry, PsoBest, found conventional systemic and biologic drugs for psoriasis demonstrated relative safety from serious adverse events in patients between January 2008–December 2012…... [Read More]

Filed Under: Biologics & Biosimilars, Drug Updates Tagged With: Biologics, Germany, metho­trexate, Psoriasis

  • « Previous Page
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • …
  • 43
  • Next Page »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

This site uses cookies: Find out more.